ASML vs PFE: Which Is the Better Buy?

Side-by-side comparison of ASML Holding N.V. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-22.
ASML Holding N.V. · Technology
$1,458.97
+65.1% upside to fair value
Grade B High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
ASML has more upside to fair value (+65.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ASML PFE
Current Price $1,458.97 $26.91
Fair Value Estimate $2,408.73 $35.00
Upside to Fair Value +65.1% +30.1%
Market Cap $562.3B $153.0B
Forward P/E 48.3x 9.5x
EV / EBITDA 37.6x 13.8x
Price / Sales 14.4x 2.4x
Price / FCF 54.4x 16.8x
Revenue Growth YoY +13.2% -1.6%
Gross Margin 52.6% 70.3%
Operating Margin 34.8% 24.7%
Return on Equity 52.0% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 1.84% 5.9%
Analyst Consensus Strong Buy Hold
Investment Thesis
ASML — ASML Holding N.V.
ASML Holding N.V. is a leading technology company specializing in semiconductor manufacturing equipment, particularly extreme ultraviolet lithography machines which hold a near-monopoly position. The company benefits from a durable competitive moat driven by its technological leadership, high barriers to entry, and strong demand from semiconductor manufacturers globally, especially in China. Desp…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric ASML PFE
Zone Low $1,806.55 $25.00
Zone High $2,047.42 $29.00
In Buy Zone? Yes Yes
← ASML Research    PFE Research →    All Research